Loading company…
San Diego biotech Pipeline Therapeutics develops small molecules for neuroregeneration, including candidates for hearing loss and multiple sclerosis.
Founded in 2017 and based in California, US, Pipeline Therapeutics Inc. develops small-molecule neuroregeneration treatments covering synaptogenesis, remyelination and axonal repair. PIPE-505, a gamma-secretase inhibitor, targets mild-to-moderate sensorineural hearing loss linked to cochlear synaptopathy, while PIPE-307 addresses remyelination and axonal repair in conditions including multiple sclerosis. Carmine Stengone has been president and CEO since 2018.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in